echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical application of ASKC852 tablets of Osaikang was undertaken by CDE

    The clinical application of ASKC852 tablets of Osaikang was undertaken by CDE

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On April 23, Osaikang declared a new drug clinical application for the first class of new drug ASKC852 tablets, which was undertaken by CDE, which is a small molecule immunomodulatory drug.
    Since 2021, the company has declared two new drugs.
    The dexlansoprazole for injection, which was previously declared for marketing, is a class 2.
    2 new drug and is currently under review.

    Figure 1: The new drug that Osaikang has declared for clinical use this time

    Source: CDE official website

    According to data, ASKC852 is a new class 1 drug jointly developed by Aosaekang and Shanghai WuXi AppTec.
    It is a new small molecule immunomodulatory drug that can inhibit the phosphorylation of SMAD protein (pSMAD) with high selectivity and efficiency both in vivo and in vitro.
    Thereby, the growth and progression of tumors can be inhibited from a variety of ways, including inhibiting the epithelial-mesenchymal transition (EMT) and metastasis of tumors, enhancing the anti-tumor immune response in the tumor microenvironment, and inhibiting angiogenesis in the tumor.

    In the earlier pharmacodynamic experiment, ASKC852 single agent can have a significant inhibitory effect on tumors, and when combined with PD-L1 monoclonal antibody, it can also produce excellent synergistic effects, making PD-L1 monoclonal antibody anti-tumor effect Significantly improved.
    In addition, in another anti-metastatic model, ASKC852 also has a significant inhibitory effect on tumor metastasis to lung, liver, kidney, intestine and other organs.

    Figure 2: New drugs declared and under review by Osaikang this year

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    Since 2021, Osaikang has applied for two new drugs.
    Among them, the new drug application for dexlansoprazole for injection, which was declared in January, is under review and approval.

    It is reported that dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazole.
    Dexlansoprazole enteric-coated capsules by Takeda Pharmaceuticals are used for the treatment of various degrees of erosive esophagitis, non-erosive reflux esophagitis and maintenance treatment of related symptoms.
    Currently, there is no dexlansoprazole injection on the market worldwide.
    Compared with L-body and racemate, dexlansoprazole has better pharmacokinetics and pharmacodynamic properties, thereby exerting a stronger and longer-lasting acid suppression effect.

    Table 1: Part of the latest developments of Aosaiken's Class 1 and Class 2 new drugs

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    Aosaikang is currently a leading domestic enterprise in the subdivision of anti-peptic ulcer proton pump inhibitor injection products.
    As the main theme of the pharmaceutical industry shifts from imitation to innovation, the company has also increased investment in new product research and development in recent years, and the main focus of research products In the four therapeutic areas of anti-peptic ulcer, anti-tumor, anti-drug-resistant bacterial infection, and chronic diseases, judging from the current progress, a number of innovative drugs have entered the harvest period, of which ASK120067 tablets have entered phase III clinical trials.

    Source: Minet database, CDE official website

    The review data statistics are as of April 26, if there are any errors or omissions, please correct me.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.